Delivery Order SPE2DB22D3004-SPE2DB25FQU08
- Not listed
- The Defense Logistics Agency awarded a $1,877.45 delivery order to AmerisourceBergen Drug Corp for XCOPRI 200 mg tablets (30-count units) on June 16, 2025, with a completion date of June 17, 2025. This firm fixed-price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $1,768.44 delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count supply) under a firm fixed price contract type. The award was issued on June 2, 2025, with an ultimate completion date of June 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count packages) under a firm fixed-price contract with a ceiling value of $1,712.07. The order was competitively awarded without set-aside designation and has an ultimate completion date of November 25, 2025. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,794.10 to AmerisourceBergen Drug Corp for XCOPRI 150 mg tablets (30-count supply) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 200 MG tablets (30-count) valued at $1,712.07 under a firm fixed-price contract type. The award was made on November 4, 2025, with an ultimate completion date of November 5, 2025, and represents a non-set-aside, competitively awarded procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $3,536.88 delivery order to AmerisourceBergen Drug Corp for XCOPRI 25 mg tablets (30-count units) with a firm fixed price structure. The contract, which was competitively awarded without set-aside designation, is scheduled for completion by June 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,090.00 to AmerisourceBergen Drug Corp for XCOPRI 100 MG tablets (30-count packaging) on November 14, 2025, with an ultimate completion date of November 17, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) under a firm fixed-price contract valued at $2,152.35. The contract was competitively awarded without set-aside designation and has an ultimate completion date of November 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $3,219.60 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count units) with an ultimate completion date of August 28, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor headquartered in Conshohocken, Pennsylvania. The contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,874.46 to AmerisourceBergen Drug Corp for XCOPRI 50 mg tablets (30-count supply) under a firm fixed-price contract. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FQU08Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XCOPRI 100 mg tablets (30-count) on May 20, 2025, with a ceiling value of $1,979.46 under a firm fixed-price contract type. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was made through open competition with no set-aside designation, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XCOPRI is a brand-name neurological medication, consistent with AmerisourceBergen's extensive federal pharmaceutical distribution portfolio supporting military and veteran healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement needs through the DLA's global pharmaceutical support programs. The company's comprehensive IDC vehicle enables it to supply a broad range of pharmaceutical products, medical supplies, vaccines, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. This delivery order for XCOPRI exemplifies the company's role in fulfilling specialized medication requirements within the DLA's strategic medical supply chain, with an ultimate completion date of May 21, 2025.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 5/20/25 |